Neuland Laboratories Ltd., a pharmaceutical manufacturer of APIs, complex intermediates, and contract services provider, has opened a new manufacturing facility in Pashamylaram, Hyderabad as part of its collaboration with Tokyo-based API Corp. (APIC), a unit of Mitsubishi Chemical Holdings Group that produces APIs, intermediates and investigational new drugs. The new facility is APIC’s first outside of Japan. Neuland will operate the manufacturing facilities to provide APIC with additional capacity for pharmaceutical APIs and intermediates.
 
Kiyoshi Kondo, president and chief executive officer of APIC, stated, “We welcome the inauguration of our dedicated Neuland manufacturing facility, a world-class operation that has come online just a year after our collaboration agreement was signed. This facility will benefit our growing customer base by rapidly increasing our capacity to deliver high quality, competitively-priced APIs and intermediates in partnership with Neuland, a company with a long history of outstanding quality and regulatory excellence.”
 
“We are pleased to inaugurate these new state-of-the-art manufacturing facilities developed as part of our collaboration with APIC,” said Dr. D.R. Rao, Chairman and Managing Director of Neuland Labs Ltd. “This arrangement allows APIC to expand their business in Japan in a timely and cost-effective way, while also helping to raise Neuland’s profile as a quality supplier of APIs and intermediates to the Japanese market.”